No role for routine balloon pump in high-risk percutaneous coronary intervention (PCI)

In patients with severe left ventricular dysfunction, PCI is associated with significant morbidity and mortality, particularly if large amounts of viable myocardium are supplied by the diseased coronary arteries. Although observational studies have suggested that intra-aortic balloon pump (IABP) insertion may decrease patient risk in this setting, no previous randomised controlled trial has examined this […]

Read More…

Targeting valvular heart disease

The prevalence of valvular heart disease, in particular stenotic aortic disease, increases with age and reaches 13% in individuals over the age of 75 years. Despite this the aetiology and molecular mechanisms remain unclear, although several lines of evidence have suggested that its pathogenesis shares similarities to atherosclerotic disease, namely infiltration of inflammatory cells and […]

Read More…

Rosiglitazone linked to increased vascular events

In 2007 a meta-anlaysis of 42 randomised trials involving rosiglitazone found a 1.4 fold increase in the risk of acute myocardial infarction (AMI) compared with non-thiazolidinedione therapies. Subsequently, a metaanalysis of 19 pioglitazone trials found a significant reduction in a composite outcome of non-fatal AMI, stroke and all-cause mortality. Therefore, this study set out to […]

Read More…

Self-monitoring of hypertension in primary practice

Despite substantial advances in lifestyle and pharmaceutical interventions, only half of people on treatment for hypertension have their blood pressure controlled to current recommended levels. Patient selfmanagement with self-titration (ie, adjustment) of antihypertensive drugs has previously only been tested on a small scale, therefore this study assessed whether self-management by people with poorly controlled hypertension […]

Read More…

Next generation coronary stents go head to head

First generation drug eluting stents (DES) are now a decade old, and several second generation DES have now entered the market. The Xience V or Promus everolimus-eluting stent has been accruing impressive data to suggest improved outcomes for restenosis and major adverse cardiac events, coupled with significantly improved deliverability. The Endeavour zotarolimus eluting stent however […]

Read More…

Second generation everolimus stent raises the stakes

Drug eluting stents, generally coated with either paclitaxel or sirolimus, have revolutionised the practice of interventional cardiology, markedly reducing the incidence of restenosis and the need for repeat procedures.  Nevertheless, restenosis still occurs and the slower re-epithelialisation associated with these stents mandates the prolonged use of dual antiplatelet therapy to avoid potentially catastrophic stent thrombosis.  […]

Read More…

Modern Trends in Myocardial Infarction

Heart disease, and in particular coronary heart disease, is the leading cause of death worldwide but rates have actually been declining since the 1950s likely due to reductions in smoking prevalence and the availability of effective treatments for hypertension.  Consequently, rates of death from acute myocardial infarction (MI) have also been falling but there is […]

Read More…

Little Change in Prognosis for Ventricular Septal Rupture

Ventricular septal rupture following myocardial infarction is a rare but potentially catastrophic complication.  Current ACC and AHA guidelines recommend immediate operative intervention in patients with postinfarction ruptures, regardless of their clinical status, but surgical repair remains very challenging with reported in-hospital mortality being reported in the range of 20-60%. […]

Read More…